Sandu Pharmaceuticals Stock Plummets to New 52-Week Low at Rs. 40.21

Sandu Pharmaceuticals has reached a significant milestone by hitting a new 52-week low of Rs. 40.21 on November 17, 2025. This decline reflects a broader trend of underperformance, as the stock has lagged behind its sector by 1.61% today. Over the past year, Sandu Pharmaceuticals has seen a notable decrease of 24.53%, contrasting sharply with the Sensex's positive performance of 9.20%.
The company's stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a sustained downward trend. Despite the broader market, which saw the Sensex open higher and approach its 52-week high, Sandu Pharmaceuticals continues to struggle with weak long-term fundamentals. The company has reported a modest annual growth rate in net sales of 4.69% and an operating profit growth of 17.92% over the last five years.

With a return on equity of just 3.73% and a concerning EBIT to interest ratio of 1.92, the financial health of Sandu Pharmaceuticals raises questions about its ability to service debt effectively. As the stock navigates these challenges, it remains to be seen how it will adapt in the current market landscape.